enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Androgen deprivation therapy - Wikipedia

   en.wikipedia.org/wiki/Androgen_deprivation_therapy

   Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

3. Leuprorelin - Wikipedia

   en.wikipedia.org/wiki/Leuprorelin

   Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]

4. JNJ-26146900 - Wikipedia

   en.wikipedia.org/wiki/JNJ-26146900

   The drug is a nonsteroidal androgen receptor (AR) modulator with mixed agonistic and antagonistic (antiandrogenic) effects. [2] [6] In animals, it partially prevents castration-induced loss of body weight, lean body mass (LBM), and bone and reduces prostate weight and prostate tumor growth.

5. 7 Alternatives to Chemotherapy for Lymphoma in Dogs - AOL

   www.aol.com/7-alternatives-chemotherapy-lymphoma...

   1. Ketogenic Diet. Cancer cells rely on glucose for energy to grow. The ketogenic diet is a way to provide an alternative energy source to normal cells in the dog's body while starving the cancer ...

6. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

7. Comparison of bicalutamide with other antiandrogens

   en.wikipedia.org/wiki/Comparison_of_bicalutamide...

   [78] [79] [80] Of the SAAs, CPA is the only one that has been widely used in the treatment of prostate cancer. [28]: 488 As antiandrogens, the SAAs have largely been replaced by the NSAAs and are now rarely used in the treatment of prostate cancer, due to the superior selectivity, efficacy, and tolerability profiles of NSAAs.